How to buy Inventiva S-A stock - 22 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Inventiva S-A stock

Own Inventiva S-A stock in just a few minutes.

Inventiva S.A is a biotechnology business based in the US. Inventiva S-A shares (IVA) are listed on the NASDAQ and all prices are listed in US Dollars. Inventiva S-A employs 88 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Inventiva S-A

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IVA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Inventiva S-A share price

Use our graph to track the performance of IVA stocks over time.

Inventiva S-A shares at a glance

Information last updated 2021-04-15.
52-week range$9.01 - $19.06
50-day moving average $14.14
200-day moving average $14.08
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.32

Buy Inventiva S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inventiva S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inventiva S-A financials

Revenue TTM $5.3 million
Gross profit TTM $4.4 million
Return on assets TTM -20.82%
Return on equity TTM -44.06%
Profit margin 0%
Book value N/A
Market capitalisation $518.7 million

TTM: trailing 12 months

Shorting Inventiva S-A shares

There are currently 208,740 Inventiva S-A shares held short by investors – that's known as Inventiva S-A's "short interest". This figure is 14.8% up from 181,840 last month.

There are a few different ways that this level of interest in shorting Inventiva S-A shares can be evaluated.

Inventiva S-A's "short interest ratio" (SIR)

Inventiva S-A's "short interest ratio" (SIR) is the quantity of Inventiva S-A shares currently shorted divided by the average quantity of Inventiva S-A shares traded daily (recently around 38371.323529412). Inventiva S-A's SIR currently stands at 5.44. In other words for every 100,000 Inventiva S-A shares traded daily on the market, roughly 5440 shares are currently held short.

However Inventiva S-A's short interest can also be evaluated against the total number of Inventiva S-A shares, or, against the total number of tradable Inventiva S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inventiva S-A's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inventiva S-A shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Inventiva S-A shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Inventiva S-A.

Find out more about how you can short Inventiva S-A stock.

Inventiva S-A share dividends

We're not expecting Inventiva S-A to pay a dividend over the next 12 months.

Inventiva S-A share price volatility

Over the last 12 months, Inventiva S-A's shares have ranged in value from as little as $9.01 up to $19.0636. A popular way to gauge a stock's volatility is its "beta".

IVA.US volatility(beta: 0.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inventiva S-A's is 0.9433. This would suggest that Inventiva S-A's shares are less volatile than average (for this exchange).

Inventiva S-A overview

Inventiva S. A. , a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site